Table 1 Calcium related genes suspects to human prostatic tumorigenesis
Genes | Cases_Altered % (cases) | Sources of data bases | |||||
|---|---|---|---|---|---|---|---|
TCGA Provisional 498 patients/499 samples | TCGA cell 2015 333 patients/333 samples | NEPC 2016 81 patients/114 samples | FHCRC, 2016 63 patients/176 samples | MICH 59 patients/61 samples | SU2C 150 patients/150 samples | ||
PTEN | Mutation | 1.2% (6) | 1.5% (5) | 0.88% (1) | 1.7% (3) | 8.2% (5) | 7.33% (11) |
Amplification | 0 | 0 | 7.02% (8) | 0 | 0 | 0 | |
Deep deletion | 4.21% (21) | 4.5% (15) | 14.91% (17) | 7.95% (14) | 39.34% (24) | 26% (39) | |
mRNA/protein ↓ | 8.01% (40) | 9.01% (30) | 0 | 18.18% (32) | 0 | 2% (3) | |
Multiple alteration | 16.23% (81) | 11.41% (38) | 0.88% (1) | 23.3% (41) | 1.64% (1) | 6.66% (10) | |
Patients_Altered | 30% (147) | 26% (88) | 30% (24) | 63% (40) | 51% (30) | 42% (63) | |
RYR1 RYR2 RYR3 | Mutation | 6.61% (33) | 3.9% (13) | 7.02% (8) | 9.09% (16) | 14.75% (9) | 15.33% (23) |
Amplification | 1.4% (7) | 1.5% (5) | 27.19% (31) | 3.41% (6) | 1.64% (1) | 1.33% (2) | |
Deep deletion | 3.61% (18) | 3.9% (13) | 0.88% (1) | 1.14% (2) | 0 | 1.33% (2) | |
mRNA/protein ↓ | 7.62% (38) | 8.11% (27) | 0 | 14.2% (25) | 0 | 6% (9) | |
Multiple alteration | 2% (10) | 0.6% (2) | 3.51% (4) | 1.7% (3) | 3.28% (2) | 0.67% (1) | |
Patients_Altered | 21% (106) | 18% (60) | 44% (36) | 43% (27) | 20% (12) | 25% (37) | |
RYR1 RYR2 RYR3 FKBP1A FKBP1B | Mutation | 6.01% (30) | 3.6% (12) | 7.02% (8) | 6.82% (12) | 14.75% (9) | 14.67% (22) |
Amplification | 1.4% (7) | 1.8% (6) | 28.95% (33) | 3.41% (6) | 1.64% (1) | 1.33% (2) | |
Deep deletion | 4.21% (21) | 4.2% (14) | 0.88% (1) | 1.14% (2) | 1.64% (1) | 1.33% (2) | |
mRNA/protein ↓ | 14.83% (74) | 13.21% (44) | 0 | 21.02% (37) | 0 | 8% (12) | |
Multiple alteration | 3.01% (15) | 1.2% (4) | 3.51% (4) | 5.11% (9) | 3.28% (2) | 1.33% (2) | |
Patients_Altered | 30% (147) | 24% (80) | 47% (38) | 52% (33) | 22% (13) | 27% (40) | |
IP3R1 IP3R2 IP3R3 | Mutation | 2.81% (14) | 1.8% (6) | 3.51% (4) | 3.98% (7) | 4.92% (3) | 2.67% (4) |
Amplification | 0.4% (2) | 0.3% (1) | 26.32% (30) | 5.68% (10) | 1.64% (1) | 3.33% (5) | |
Deep deletion | 2% (10) | 2.7% (9) | 0.88% (1) | 0 | 3.28% (2) | 0 | |
mRNA/protein ↓ | 10.62% (53) | 9.91% (33) | 0 | 11.93% (21) | 0 | 6.67% (10) | |
Multiple alteration | 1.2% (6) | 0.6% (2) | 0 | 0.57% (1) | 0 | 2.67% (4) | |
Patients_Altered | 17% (85) | 15% (51) | 38% (31) | 33% (21) | 10% (6) | 15% (23) | |
IP3R1 IP3R2 IP3R3 PP2AA PP2AB PP2AC | Mutation | 1.8% (9) | 2.1% (7) | 4.39% (5) | 2.84% (5) | 8.2% (5) | 2% (3) |
Amplification | 0.8% (4) | 0.6% (2) | 34.21% (39) | 5.11% (9) | 4.92% (3) | 2% (3) | |
Deep deletion | 11.82% (59) | 12.31% (41) | 1.75% (2) | 2.27% (4) | 14.75% (9) | 4% (6) | |
mRNA/protein ↓ | 22.44% (112) | 20.72% (69) | 0 | 30.68% (54) | 0 | 15.33% (23) | |
Multiple alteration | 8.22% (41) | 6.01% (20) | 0 | 7.39% (13) | 1.64% (1) | 9.33% (14) | |
Patients_Altered | 45% (224) | 42% (139) | 47% (38) | 68% (43) | 31% (18) | 33% (49) | |
CaSR | Mutation | 0.6% (3) | 0.6% (2) | 0 | 0 | 1.64% (1) | 2% (3) |
Amplification | 0.8% (4) | 0.6% (2) | 17.54% (20) | 3.41% (6) | 3.28% (2) | 0.67% (1) | |
Deep deletion | 0.8% (4) | 0.6% (2) | 0 | 0.57% (1) | 0 | 0 | |
mRNA/protein ↓ | 2.2% (11) | 1.2% (4) | 0 | 3.41% (6) | 0 | 2% (3) | |
Multiple alteration | 0 | 0 | 0.88% (1) | 0 | 0 | 0.67% (1) | |
Patients_Altered | 4% (22) | 3% (10) | 25% (20) | 13% (8) | 5% (3) | 5% (8) | |